Hyunjung Lee

Dr. Hyunjung Lee

Dongguk University College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HLHyunjung Lee
Hyunjung Lee
KKKui-Jin Kim
Kui-Jin Kim
JSJi Hea Sung
Ji Hea Sung
MNMilang Nam
Milang Nam
KSKoung Jin Suh
Koung Jin Suh
JKJee Hyun Kim
Jee Hyun Kim
Targeting cell cycle regulation in colorectal cancer has not been fully evaluated. We investigated the efficacy of the CDK4/6 inhibitor, abemaciclib, and confirmed a synergistic interaction for PI3K p110α and CDK dual inhibition in colorectal cancer cell lines. Caco-2 and SNU-C4 cell lines were selected to explore the mechanism of action for and resistance to abemaciclib. In vitro and in vivo models were used to validate the anti-tumor activity of abemaciclib monotherapy and BYL719 combination therapy. Abemaciclib monotherapy inhibited cell cycle progression and proliferation in Caco-2 and SNU-C4 cells. CDK2-mediated Rb phosphorylation and AKT phosphorylation appeared to be potential resistance mechanisms to abemaciclib monotherapy. Abemaciclib/BYL719 combination therapy demonstrated synergistic effects regardless of PIK3CA mutation status but showed greater efficacy in the PIK3CA mutated SNU-C4 cell line. Growth inhibition, cell cycle arrest, and migration inhibition were confirmed as mechanisms of action for this combination. In an SNU-C4 mouse xenograft model, abemaciclib/BYL719 combination resulted in tumor growth inhibition and apoptosis with tolerable toxicity. Dual blockade of PI3K p110α and CDK4/6 showed synergistic anti-tumor effects in vivo and in vitro in human colorectal cancer cell lines. This combination could be a promising candidate for the treatment of patients with advanced colorectal cancer.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HLHyunjung Lee
Hyunjung Lee
HPHaeyong Pak
Haeyong Pak
JHJae Joon Han
Jae Joon Han
MCMyung Hee Chang
Myung Hee Chang
Lee HJ, et al. J Korean Med Sci. 2023 Sep;38(37):e299. https://doi.org/10.3346/jkms.2023.38.e299

1 December 2021 in The Korean Journal of Hospice and Palliative Care
Verified
Journal Article
Open access
PDF file
DKDalyong Kim
Dalyong Kim
HLHyunjung Lee
Hyunjung Lee
SYSoo-Young Yu
Soo-Young Yu
JKJung Hye Kwon
Jung Hye Kwon
HAHee Kyung Ahn
Hee Kyung Ahn
SSSUNG JOON SHIN
SUNG JOON SHIN
Dalyong Kim, M.D., Hyun Jung Lee, Ph.D., Soo-Young Yu, Ph.D., M.P.H., Jung Hye Kwon, Ph.D., Hee Kyung Ahn, Ph.D., Jee Hyun Kim, Ph.D., Seyoung Seo, Ph.D., Chi Hoon Maeng, Ph.D., Seungtaek Lim, M.D., Do Yeun Kim, Ph.D. and Sung Joon Shin, Ph.D.. J Hosp Palliat Care 2021;24:204-13. https://doi.org/10.14475/jhpc.2021.24.4.204

10 December 2021 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
JPJun Kyeong Park
Jun Kyeong Park
ELEun Ja Lee
Eun Ja Lee
DKDong-Eog Kim
Dong-Eog Kim
HLHyunjung Lee
Hyunjung Lee
박준경, et al. J Korean Soc Radiol. 2022 Jan;83(1):178-183. https://doi.org/10.3348/jksr.2021.0106

1 January 2018 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
JLJung Eun Lee
Jung Eun Lee
HHHee Jin Huh
Hee Jin Huh
JCJae-Woo Chung
Jae-Woo Chung
ELEun Kyoung Lee
Eun Kyoung Lee
HLHyunjung Lee
Hyunjung Lee

26 October 2026 in Blood Research
Verified
Journal Article
Open access
PDF file
YPYewon Park
Yewon Park
HLHyunjung Lee
Hyunjung Lee
Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated hemolysis. Although C5 inhibitors effectively control intravascular hemolysis, some patients develop clinically significant extravascular hemolysis (EVH) because of upstream C3 deposition. Case A 56-year-old woman was diagnosed with PNH in 2019 and managed with intermittent transfusions. In October 2024, she developed progressive renal dysfunction; the PNH clone size was 95.72%. Ravulizumab was initiated in March 2025. Although the lactate dehydrogenase (LDH) level normalized after ravulizumab initiation, her hemoglobin (Hb) level remained below 10 g/dL, with marked reticulocytosis and continued transfusion requirements after more than 6 months of treatment. Danicopan, a factor D inhibitor, was added in November 2025. Subsequently, her Hb level exceeded 10 g/dL, reticulocyte counts gradually decreased, and transfusion dependence declined. Discussion This case demonstrates that adding danicopan to ravulizumab can reduce residual EVH and improve anemia in patients with PNH receiving C5 inhibitor therapy.